Navigation Links
Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology

he Saint Louis University School of Medicine, said, "The potential identification of an etiology for chronic sinusitis, and the subsequent development of an effective pharmacotherapy, would represent an important advance in the treatment of patients suffering from surgery refractory chronic sinusitis. This is one of the most common chronic illnesses, affecting millions, and the potential of intranasal antifungals to significantly reduce morbidity is tremendous."

Accentia has received Fast Track status from the Food and Drug Administration for SinuNase, and has initiated a Phase 3 clinical trial at sites across the U.S., in patients with severe chronic sinusitis who have had one or more prior sinus surgeries. Patients who believe they may be eligible to participate in a clinical trial with SinuNase are encouraged to visit www.accentia.net/patients/trials_sinunase.php, or call 212-686-4100.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage "disruptive" clinical products, especially for already-approved drugs in new formulations and/or new indications that are patent-protected and which represent new therapeutics with greater clinical and economic value. Accentia has a pipeline of products in late-stage clinical development. The company's lead respiratory product candidate is SinuNase(TM), which is under clinical development to treat chronic sinusitis (rhinosinusitis). SinuNase is a novel application and formulation of a known anti-fungal exclusively licensed from the Mayo Foundation for Medical Education and Research. The product has been Fast Tracked by the FDA and the Company has commenced a Phase 3 clinical trial. The Company's other lead product is BiovaxID(TM), a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed by Accentia's subsidiary, Biovest International, Inc., (OTCB
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
11. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
Post Your Comments:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Pa., June 30, 2011 Endo Pharmaceuticals (Nasdaq: ... study comparing the novel investigational drug axomadol against placebo in ... back pain. The results indicate that axomadol did not meet ... analyses of the data and evaluating the path forward for ...
... 30, 2011 UCB and Harvard University officially launched ... took place in Boston last night in the presence ... (Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 ) The ... and academia, with Harvard scientists continuing their research that ...
Cached Medicine Technology:Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain 2UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3
(Date:7/10/2014)... (HealthDay News) -- Most professional football players who have ... game, a new study finds. Shoulder instability is ... of return after surgery to fix the problem has ... study included 60 players who had shoulder stabilization surgery. ... returned to play, defined as playing in at least ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... help ease the hot flashes that often accompany menopause, new ... than 50 percent of menopausal women, said Dr. Taraneh Shirazian, ... at the Icahn School of Medicine at Mount Sinai Hospital ... more than 10 hot flashes a day, and she added ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... of 10 adults make use of calorie information on menus, ... according to a new U.S. study. Women in particular ... Hee Lee-Kwan, an epidemiologist with the U.S. Centers for Disease ... they used menu labeling to help choose their meal, compared ...
(Date:7/10/2014)... than 200 experts on aggression, who research issues ranging ... the 21st World Meeting of the International Society for ... July 15-19. , Georgia State University is hosting the ... on alternating continents. , "We are excited to be ... countries, which will help produce fresh ideas about the ...
(Date:7/10/2014)... the top public health concerns in the United States, ... obese as of 2012. As health problems such as ... Twitter to discuss the problem. , A new study, ... the Brown School at Washington University in St. Louis, ... to track Twitter conversations about the issue of overweight ...
Breaking Medicine News(10 mins):Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:Study looks at how Twitter can be used to address specific health issues 2
... data from Understanding Society based on 14,000 UK households found ... higher levels of education and by married people. The ... with those in routine occupations reporting worse sleep than those ... University of Surrey who analysed the findings said: "Given the ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) -- ... seven hours a night, which affects their concentration and ... also impairs work performance and the ability to drive ... Control and Prevention (CDC), which published two sleep studies ...
... The combined effects of chemotherapy and endocrine therapy ... cancer survivors. In a study scheduled for publication in ... Medicine and Rehabilitation , researchers from the Oregon Health ... breast cancer survivors whether they had fallen in the ...
... An analysis of breast tissue may help doctors better predict ... Researchers analyzed what they describe as "highways" of connective ... collagen fibers -- the main component of connective tissue -- ... determine treatment. Collagen not only surrounds most body organs ...
... -- New findings about brain rhythms could lead to the ... A team at Massachusetts General Hospital found that a brain ... hidden form during sleep, where it becomes more intense at ... to being awakened by noise or other disturbances. To ...
... The burning, tingling pain of neuropathy may affect feet ... of nerve cells that supply the extremities age and ... these areas, Johns Hopkins scientists suggest in a new ... to fight neuropathy, a condition that often accompanies other ...
Cached Medicine News:Health News:The better off sleep better 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 2Health News:1 in 3 Americans Gets Less Than 7 Hours of Sleep: CDC 3Health News:Breast cancer survivors at higher risk for falls 2Health News:Tissue Analysis May Help Predict Breast Cancer Outcome 2Health News:Particular Brain Rhythm in Sleep Makes You More Vulnerable to Disturbances 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 2Health News:Feet first? Old mitochondria might be responsible for neuropathy in the extremities 3
ELISA kit for CMV CAP M....
Cytomegalovirus IgG ELISA....
Cytomegalovirus IgM ELISA....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Medicine Products: